From The Stage

Cell and Gene Therapies Account for a Large Portion of the Therapeutics Market

Posted by BioAgilytix / / Gene Therapy, Industry Update

Cell and gene therapies have gone through a growth spurt in the last decade. According to data from the Alliance for Regenerative Medicine (ARM), during the first three quarters of 2020, regenerative medicine research and development broke records at nearly $16 billion in global financing. From the treatment of knee injuries to osteoarthritis, certain cancers and even muscular dystrophy, advances in gene and cell therapies have definitely caught the attention of medical professionals, and for good reason. Cell and Gene Therapies Account for a Large Portion of Therapeutic Market Share…

The Power of Being NYCE

Posted by / / Gene Therapy, Industry Update

A recent study using triple-edited ‘NYCE’ cells shows the possibilities of multiplex genome editing to effectively treat complex diseases like some cancers. We explore the promising results.

CLIA Requirements for Gene and Cell Therapy Programs

Posted by / / Cell Therapy, Gene Therapy, Regulatory Considerations

It's a common misconception that all aspects of cell & gene therapy research and development are excluded from CLIA oversight. We take a closer look at testing and when CLIA requirements apply.

Vector Innovation to Improve Gene Therapy Safety: A Credit to Scientific Tenacity

Posted by / / BioAgilytix Insight, Gene Therapy

A new clinical trial by St. Jude Children’s Research Hospital for the treatment of SCID-X1 highlights a major advancement in gene therapy safety over recent years, in this case spurred by scientists who were courageous enough to push forward the development of safer vectors to overcome serious adverse events (SAEs) that were resulting from the previous generation of gene therapies developed for SCID-X1.

A History of Gene Therapy: Exploring Lessons Learned In Light of New Approvals

Posted by / / BioAgilytix Insight, Gene Therapy

The FDA recently approved the first gene therapy for pediatric patients with SMA, signifying a major step forward for the therapeutic field as a whole. To continue this progress, it is important that we understand the key principles and events in gene therapy’s history that have led us to where we are today.